Abstract
The pharmaceutical industry is developing increasing numbers of drugs and diagnostics based on nanoparticles, and evaluating the immune response to these diverse formulations has become a challenge for scientists and regulatory agencies alike. An international panel of scientists and representatives from various agencies and companies reviewed the imitations of current tests at a workshop held at the National Cancer Institute in Frederick, Maryland. This article outlines practical strategies for identifying and controlling interferences in common evaluation methods and the implications for regulation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
US Food and Drug Administration Report of the FDA Nanotechnology Task Force (FDA, 2007); available at: <http://tinyurl.com/n6c2zl>.
European Medicines Agency Reflection Paper on Nanotechnology-Based Medicinal Products for Human Use (EMEA, 2006); available at <http://www.emea.europa.eu/pdfs/human/genetherapy/7976906en.pdf>.
http://ncl.cancer.gov/nanoparticle_immunotoxicity_workshop.asp.
Vallhov, H. et al. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett. 6, 1682–1686 (2006).
Dean, J. H. Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals Toxicology 119, 95–101 (1997).
Dobrovolskaia, M. A. & McNeil, S. E. Immunological properties of engineered nanomaterials. Nature Nanotech. 2, 469–478 (2007).
Weaver, J. L. et al. Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions. J. Immunotoxicol. 2, 11–20 (2005).
Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnol. 25, 1159–1164 (2007).
Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404–1413 (2008).
Moghimi, S. M. & Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid. Res. 42, 463–478 (2003).
Pessina, A. et al. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 75, 355–367 (2003).
US Food and Drug Administration Immunotoxicology Evaluation of Investigational New Drugs (FDA, 2002); available at <http://tinyurl.com/mn3n47>.
Fifis, T. et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148–3154 (2004).
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary information
Supplementary information (PDF 1476 kb)
Rights and permissions
About this article
Cite this article
Dobrovolskaia, M., Germolec, D. & Weaver, J. Evaluation of nanoparticle immunotoxicity. Nature Nanotech 4, 411–414 (2009). https://doi.org/10.1038/nnano.2009.175
Published:
Issue Date:
DOI: https://doi.org/10.1038/nnano.2009.175
This article is cited by
-
Membrane-wrapped nanoparticles for photothermal cancer therapy
Nano Convergence (2022)
-
RNA m6A Alterations Induced by Biomineralization Nanoparticles: A Proof-of-Concept Study of Epitranscriptomics for Nanotoxicity Evaluation
Nanoscale Research Letters (2022)
-
Applications of nanodiamonds in the diagnosis and treatment of neurological diseases
Journal of Nanoparticle Research (2022)
-
Considerations for designing preclinical cancer immune nanomedicine studies
Nature Nanotechnology (2021)
-
Antibiofilm effects of N,O-acetals derived from 2-amino-1,4-naphthoquinone are associated with downregulation of important global virulence regulators in methicillin-resistant Staphylococcus aureus
Scientific Reports (2020)